Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ASTNYSEAMERICAN:SYNNYSE:TRP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsTRPTC Energy$47.40-0.7%$49.65$37.07▼$51.99$49.31B0.782.48 million shs2.26 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%TRPTC Energy-0.73%-4.33%-4.95%-2.16%+24.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ATRPTC Energy4.3902 of 5 stars3.44.01.70.82.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTAsterias Biotherapeutics 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ATRPTC Energy 2.83Moderate Buy$62.0030.81% UpsideCurrent Analyst Ratings BreakdownLatest AST, SYN, RBD, and TRP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025TRPTC EnergyCibc World MktsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/2/2025TRPTC EnergyCIBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Sector Outperform4/4/2025TRPTC EnergyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ATRPTC Energy$10.05B4.90$5.14 per share9.22$25.19 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ATRPTC Energy$3.43B$3.0315.6416.874.5629.17%11.41%3.36%7/30/2025 (Estimated)Latest AST, SYN, RBD, and TRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025TRPTC Energy$0.70$0.66-$0.04$0.65$2.57 billion$1.78 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTAsterias BiotherapeuticsN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ATRPTC Energy$2.364.98%N/A77.89%1 YearsLatest AST, SYN, RBD, and TRP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025TRPTC Energyquarterly$0.61424.9%6/30/20256/30/20257/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASTAsterias BiotherapeuticsN/AN/AN/ASYNSynthetic BiologicsN/A4.144.14TRPTC Energy1.610.700.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTAsterias BiotherapeuticsN/ASYNSynthetic Biologics74.38%TRPTC Energy83.13%Insider OwnershipCompanyInsider OwnershipASTAsterias BiotherapeuticsN/ASYNSynthetic Biologics2.15%TRPTC EnergyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableTRPTC Energy6,6681.04 billionN/AOptionableAST, SYN, RBD, and TRP HeadlinesRecent News About These CompaniesIntact Investment Management Inc. Has $20.41 Million Stake in TC Energy Corporation (NYSE:TRP)June 21 at 7:43 AM | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in TC Energy Corporation (NYSE:TRP)June 21 at 3:18 AM | marketbeat.com9,563 Shares in TC Energy Corporation (NYSE:TRP) Purchased by Good Steward Wealth Advisors LLCJune 20 at 6:33 AM | marketbeat.comCanada's TC Energy erases $199 million damages loss in Delaware appeal over Columbia takeoverJune 17, 2025 | reuters.comBell Bank Raises Position in TC Energy Co. (NYSE:TRP)June 17, 2025 | marketbeat.comTC Energy Co. (NYSE:TRP) Shares Bought by Exchange Traded Concepts LLCJune 15, 2025 | marketbeat.comPark Avenue Securities LLC Has $459,000 Stake in TC Energy Co. (NYSE:TRP)June 15, 2025 | marketbeat.comHennessy Advisors Inc. Increases Stock Holdings in TC Energy Co. (NYSE:TRP)June 14, 2025 | marketbeat.comHow to Allocate $28,000 Across Four TFSA Annual ContributionsJune 13, 2025 | msn.comUnion Bancaire Privee UBP SA Makes New $713,000 Investment in TC Energy Co. (NYSE:TRP)June 13, 2025 | marketbeat.comTC Energy Target of Unusually High Options Trading (NYSE:TRP)June 12, 2025 | marketbeat.comTower Resources rockets higher on breakthrough rig selection for Cameroon wellJune 10, 2025 | proactiveinvestors.co.ukTC Energy Co. (NYSE:TRP) Shares Sold by Cardinal Capital Management Inc.June 10, 2025 | marketbeat.comTower Resources selects rig for NJOM-3 wellJune 10, 2025 | proactiveinvestors.co.ukVolatile Oil Markets? These 3 Dividend Stocks Stay ResilientJune 9, 2025 | zacks.comTC Energy Co. (NYSE:TRP) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 7, 2025 | marketbeat.com4 High-Yield Pipeline Companies To Buy NowJune 6, 2025 | 247wallst.comWellington Management Group LLP Sells 41,950 Shares of TC Energy Co. (NYSE:TRP)June 6, 2025 | marketbeat.comCanadian regulator says Prince Rupert Gas Transmission pipeline project has startedJune 5, 2025 | msn.comHF Advisory Group LLC Boosts Stock Position in TC Energy Co. (NYSE:TRP)June 5, 2025 | marketbeat.comWhat is Zacks Research's Forecast for TC Energy Q1 Earnings?June 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveBy Nathan Reiff | May 23, 2025View NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveWhy Nebius Group Is One of the Top AI Stocks to WatchBy Thomas Hughes | June 17, 2025View Why Nebius Group Is One of the Top AI Stocks to WatchAST, SYN, RBD, and TRP Company DescriptionsAsterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.TC Energy NYSE:TRP$47.40 -0.35 (-0.74%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$47.47 +0.07 (+0.14%) As of 06/20/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Energy Corporation operates as an energy infrastructure company in North America. It operates through five segments: Canadian Natural Gas Pipelines; U.S. Natural Gas Pipelines; Mexico Natural Gas Pipelines; Liquids Pipelines; and Power and Energy Solutions. The company builds and operates a network of 93,600 kilometers of natural gas pipelines, which transports natural gas from supply basins to local distribution companies, power generation plants, industrial facilities, interconnecting pipelines, LNG export terminals, and other businesses. It also has regulated natural gas storage facilities with a total working gas capacity of 532 billion cubic feet. In addition, it has approximately 4,900 kilometers of liquids pipeline system that connects Alberta crude oil pipeline to refining markets in Illinois, Oklahoma, Texas, and the United States Gulf Coast. Further, the company owns or has interests in power generation facilities with approximately 4,600 megawatts; and owns and operates approximately 118 billion cubic feet of non-regulated natural gas storage facilities in in Alberta, Ontario, Québec, and New Brunswick. The company was formerly known as TransCanada Corporation and changed its name to TC Energy Corporation in May 2019. TC Energy Corporation was founded in 1951 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
